KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Deferred Taxes (2020 - 2025)

Boston Scientific (BSX) has disclosed Deferred Taxes for 6 consecutive years, with -$32.0 million as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 68.0% to -$32.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.0 million through Dec 2025, up 86.67% year-over-year, with the annual reading at -$12.0 million for FY2025, 86.67% up from the prior year.
  • Deferred Taxes hit -$32.0 million in Q4 2025 for Boston Scientific, down from $69.0 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $147.0 million in Q4 2023 to a low of -$100.0 million in Q4 2024.
  • Historically, Deferred Taxes has averaged -$10.8 million across 5 years, with a median of -$10.5 million in 2024.
  • Biggest five-year swings in Deferred Taxes: plummeted 7400.0% in 2022 and later skyrocketed 2000.0% in 2023.
  • Year by year, Deferred Taxes stood at -$75.0 million in 2021, then soared by 109.33% to $7.0 million in 2022, then surged by 2000.0% to $147.0 million in 2023, then crashed by 168.03% to -$100.0 million in 2024, then soared by 68.0% to -$32.0 million in 2025.
  • Business Quant data shows Deferred Taxes for BSX at -$32.0 million in Q4 2025, $69.0 million in Q3 2025, and -$90.0 million in Q2 2025.